Segment Information

6 Months Ended

Dec. 28, 2013

Segment Information [Abstract]

Segment Reporting Disclosure [Text Block]

SEGMENT INFORMATION

The Company has five reportable segments, aligned primarily by type of product: Consumer Healthcare, Nutritionals, Rx Pharmaceuticals, API, and Specialty Sciences, along with an Other category. As noted in Note 1, in conjunction with the acquisition of Elan on December 18, 2013, the Company expanded its operating segments to include the Specialty Sciences segment, which is comprised of assets focused on the treatment of Multiple Sclerosis (Tysabri®) and Alzheimer's. The accounting policies of each segment are the same as those described in the summary of significant accounting policies set forth in Note 1. The majority of corporate expenses, which generally represent shared services, are charged to operating segments as part of a corporate allocation. Unallocated expenses relate to certain corporate services that are not allocated to the segments.

	Consumer Healthcare		Nutritionals		Rx Pharma-ceuticals		API		Specialty Sciences(1)			Other		Unallocated expenses			Total(2)
Second Fiscal Quarter 2014
Net sales	$	536.3	$	139.7	$	246.6	$	30.0	$	7.4		$	19.0	$	—		$	979.0
Operating income      (loss)	$	89.5	$	13.3	$	100.4	$	8.2	$	(19.0	)	$	0.6	$	(106.4	)	$	86.6
Amortization of intangibles	$	5.3	$	7.4	$	21.5	$	0.5	$	8.7		$	0.4	$	—		$	43.8
Total assets	$	2,345.5	$	1,014.0	$	1,940.1	$	284.7	$	8,023.8		$	104.7	$	—		$	13,712.8
Second Fiscal Quarter 2013
Net sales	$	539.3	$	121.9	$	162.5	$	40.9	$	—		$	18.4	$	—		$	883.0
Operating income      (loss)	$	86.1	$	7.2	$	64.1	$	13.8	$	—		$	0.7	$	(8.0	)	$	163.9
Amortization of intangibles	$	4.9	$	7.3	$	8.5	$	0.5	$	—		$	0.4	$	—		$	21.6
Total assets	$	1,771.5	$	960.7	$	1,184.9	$	275.4	$	—		$	101.9	$	—		$	4,294.4

	Consumer Healthcare		Nutritionals		Rx Pharma-ceuticals		API		Specialty Sciences(1)			Other		Unallocated expenses			Total(2)
Year-to-Date Fiscal 2014
Net sales	$	1,074.8	$	268.7	$	450.2	$	73.2	$	7.4		$	38.1	$	—		$	1,912.4
Operating income      (loss)	$	179.5	$	21.0	$	183.5	$	30.6	$	(19.0	)	$	1.8	$	(131.2	)	$	266.2
Amortization of intangibles	$	10.6	$	14.7	$	37.7	$	1.0	$	8.7		$	0.9	$	—		$	73.6
Year-to-Date Fiscal 2013
Net sales	$	989.7	$	225.3	$	325.5	$	77.3	$	—		$	34.9	$	—		$	1,652.7
Operating income      (loss)	$	165.4	$	11.0	$	132.6	$	27.1	$	—		$	1.1	$	(16.8	)	$	320.4
Amortization of intangibles	$	7.1	$	14.6	$	16.9	$	0.9	$	—		$	0.8	$	—		$	40.3

⁽¹⁾    Specialty Sciences only includes activity from December 18, 2013 to December 28, 2013.

⁽²⁾Amounts may not cross-foot due to rounding.